Nama Insights

Danaher (DHR)

Healthcare · Diagnostics Research · NYSE

S&P 500
Danaher (DHR) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $161.86B, a trailing price-to-earnings ratio of 27.6 and a free-cash-flow yield of 3.2%. Over the most recent reported fiscal year, revenue grew 2.9% and free cash flow per share grew 2.2%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Buy · 6.6/10
Positive, at the low end of Buy. As of Nov 7, 2026.
Momentum
Middle · +3.7% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-30.6%
How far the last close sits under the highest price of the past five years.
Market cap$161.86B
Trailing P/E27.6
Price / book3.0
Price / sales6.3
FCF yield3.2%
Dividend yield0.7%
Gross margin58.6%
Operating margin20.4%
Net margin16.9%
Revenue growth (YoY)+2.9%
Revenue growth (3-yr annual)-2.7%
EPS growth (YoY)+4.1%
FCF/share growth (YoY)+2.2%
Beta0.8
ExchangeNYSE
SectorHealthcare
IndustryDiagnostics Research

DHR earnings

Next report: Jan 27, 2027 (Q4 2026, EPS estimate $2.48). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Oct 21, 2026 $2.11 $1.92 +9.9% $6.55B
Q2 2026 Jul 21, 2026 $1.94 $1.84 +5.4% $6.26B
Q1 2026 Apr 21, 2026 $2.06 $1.94 +6.2% $5.95B
Q4 2025 Jan 28, 2026 $2.23 $2.19 +1.8% $6.84B

DHR analyst price target

Median target $260.00 from 21 analysts, ranging $220.00 – $310.00.

Diagnostics Research peers

TickerCompanyMarket capP/E
TMO Thermo Fisher Scientific $257.42B 28.1
IDXX IDEXX Laboratories $53.26B 45.6
A Agilent Technologies $49.28B 28.8
WAT Waters $44.93B 31.8
IQV IQVIA $44.80B 21.2
NTRA Natera $44.78B —
MTD Mettler-Toledo International $34.51B 37.2
ILMN Illumina $32.23B 40.6
Explore live DHR data on Nama Insights →

Recent Congressional trades

Danaher trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member Chamber Trade Amount Disclosed
Kevin Hern House Sell $1,001 - $15,000 Sep 25, 2026
Kevin Hern House Sell $15,001 - $50,000 Sep 25, 2026
Alan Armstrong Senate Buy $1,001 - $15,000 Jul 21, 2026
Julie Johnson House Sell $1,001 - $15,000 Jan 15, 2026
Julia Letlow House Buy $1,001 - $15,000 Jan 13, 2026
Julie Johnson House Sell $1,001 - $15,000 Dec 11, 2025
Julie Johnson House Buy $1,001 - $15,000 Nov 14, 2025
Lisa McClain House Sell $1,001 - $15,000 Oct 22, 2025
Thomas H. Kean House Buy $1,001 - $15,000 Oct 14, 2025
Valerie Hoyle House Buy $1,001 - $15,000 Sep 12, 2025
Lisa McClain House Buy $1,001 - $15,000 Aug 13, 2025
Thomas H. Kean House Buy $1,001 - $15,000 Jul 16, 2025

DHR FAQ

Is DHR a buy?
Nama's AI scorecard currently rates Danaher Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is DHR's P/E ratio?
Danaher trades at a trailing price-to-earnings ratio of 27.6.
When does DHR report earnings?
Danaher's next scheduled report is on Jan 27, 2027. Analysts expect EPS of $2.48.
What is the DHR price target?
The median analyst price target from 21 analysts is $260.00, with a range of $220.00 – $310.00.
Is DHR Shariah compliant?
Nama's AAOIFI-style screen reads Danaher as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does DHR pay a dividend?
Yes — Danaher's dividend yield is 0.7%.

See more: Healthcare stocks →